Background. The incidence of nontuberculous mycobacterial (NTM) infections is increasing worldwide, particularly NTM lymphadenitis and skin infections (Buruli ulcer). This review summarizes the evidence for the protective effectiveness of BCG vaccination against NTM disease.
Nontuberculous mycobacteria (NTM) are ubiquitous, being found in water, soil, and animals. Although >170 species have been identified, the majority of human NTM disease is caused by <20 species [1] . In immunocompetent children, NTM most frequently cause cervicofacial lymphadenitis or skin and soft tissue infections. The commonest NTM skin infection worldwide is Buruli ulcer, a chronic, progressive skin lesion caused by Mycobacterium ulcerans. Untreated, the ulcer can progress to osteomyelitis and lead to permanent bone destruction.
Although not a notifiable disease, the incidence of NTM lymphadenitis in industrialized countries is reported to be between 0.6 and 2.2 cases per 100 000 children per year [2] [3] [4] , with the highest incidence in children <4 years of age.
Epidemiological studies in developing countries are lacking. Buruli ulcer has been reported in 33 countries, and 15 countries regularly provide data to the World Health Organization (WHO) [5] . The incidence in Africa is estimated to be between 21 and 320 cases per 100 000 per year [6, 7] in Australia, at 1 case per 100 000 per year [5, 8] , and in Japan at 0.005 cases per 100 000 per year. In Africa, about half of the cases occur in children <15 years of age, whereas in Australia and Japan approximately 15% of cases occur in this age group [5] .
Over the past few decades, the reported incidence of NTM lymphadenitis, as well as Buruli ulcer, has been increasing [6, 7, [9] [10] [11] [12] . This might be attributable partly to improved awareness, enhanced reporting, and better diagnostic methods, but it is also possible that the apparent increase is related to the discontinuation of BCG vaccination programs in industrialized countries. As BCG vaccine is a live attenuated strain of Mycobacterium bovis that shares epitopes with NTM, it is plausible that it provides specific cross-protection against NTM disease. This review and meta-analysis summarizes studies that have investigated the protective effectiveness of BCG vaccination against NTM disease in immunocompetent children and adults. • Overall protection rate reported as 47% (P = .007)
• Protection was only in the first year after vaccination (72% protective in first 6 mo)
• Protection 18% in high-incidence settings, 74% in low-incidence areas (P = . 3) was used for calculation of risk ratios, odds ratios, and the meta-analyses. Diversity in study design and reporting, which might result in selection and reporting bias, precluded quality evaluation according to the PRISMA guidelines. The ROBINS-1 tool [14] was used to assess risk of bias.
RESULTS
The literature searches yielded 812 articles relating to NTM and 1543 articles relating to Buruli ulcer. Of these, 10 fulfilled the inclusion criteria of controlled studies investigating the protective effectiveness of BCG vaccination against NTM disease in immunocompetent individuals. One study was excluded because it included the same patients as one of the other identified studies [15] .
NTM Lymphadenitis in Industrialized Countries
Three studies from industrialized countries, all population-based cohort studies, compared the incidence of NTM lymphadenitis in a total of 9 888 719 BCG-vaccinated children with 1 960 572 non-BCG-vaccinated children. Of these children, 445 were diagnosed with NTM disease. All three studies reported a greatly reduced incidence of NTM lymphadenitis in BCG-vaccinated compared to BCG-unvaccinated children; the overall risk ratio (RR) was 0.04 (95% confidence interval [CI], .01-.21]) (Table 1 and Figure 1 ). The number needed to treat (NNT) calculated from the three cohort studies was 4835 (95% CI, 4403-5362).
A nationwide surveillance study in Sweden, done after discontinuation of routine neonatal BCG vaccination, reported 387 children with confirmed extrapulmonary NTM disease (83% with Mycobacterium avium-intracellulare complex [MAC], 97% presenting with lymphadenitis) over a period of 22 years. Only nine of the 390 children had received BCG vaccine (0.02%). The cumulative incidence rate of NTM infection was 5.9 per 100 000 in BCG-vaccinated children aged <5 years and 26.8 per 100 000 in BCG-unvaccinated children [16] . Similarly, a study from the Czech Republic after discontinuation of routine BCG vaccination, in which children were screened for NTM disease by skin test, reported 27 cases of MAC lymphadenitis over a period of 6 years. All the cases occurred in BCG-unvaccinated children with an incidence of NTM lymphadenitis of 3.6 per year per 100 000 [17] . In Finland, during the period when BCG vaccine was routinely administered to newborns, the incidence of NTM lymphadenitis between 1 and 4 years of age was 0.3 per 100 000 per year in BCG-vaccinated children and 1.5-2.5 per year in BCG-unvaccinated children [18] .
Buruli Ulcer
Six studies investigated the protective effectiveness of BCG vaccination against Buruli ulcer, comparing the incidence in 6475 BCG-vaccinated adults and children with 13 612 BCGunvaccinated adults and children. The strongest evidence comes from two randomized controlled trials (RCTs) done in Uganda (Table 2 and Figure 2A ). These reported a considerably lower incidence of Buruli ulcer in BCG-vaccinated compared with BCG-unvaccinated participants, with an RR of 0.50 (95% CI, .37-.69). The NNT calculated from the three cohort studies was 4835 (95% CI, 4403-5362). Protection following BCG vaccination was higher in low-incidence than in high-incidence settings (74% vs 18%; P = .03) [19] and was only short-term (within the first year after vaccination), with an overall reduction of Buruli ulcer of 47% (P < .01) [19, 20] . In one of these studies, BCG-vaccinated individuals had smaller skin lesions compared with unvaccinated individuals [20] . Four case-control studies (two from Benin, one from Ghana, and one from the Congo, Ghana, and Togo) investigated the protective effectiveness of BCG against Buruli ulcer (Table 3) . Two studies suggest a reduced risk of Buruli ulcer in BCGvaccinated individuals [21, 22] , and two suggest no benefit [23, 24] ; when the results of all four case-control studies are combined, there is no evidence of a protective effect of BCG (odds ratio, 1.34 [95% CI, .19-1.51]) ( Figure 2B ) [21, 22, [25] [26] [27] .
Study or Subgroup

Osteomyelitis
One cohort study from Benin compared the incidence of osteomyelitis in patients with Buruli ulcer in 304 BCGvaccinated adults and children with the incidence in 68 BCGunvaccinated adults and children (Table 4 and Figure 3 ). This showed that BCG vaccination protected against the development of osteomyelitis in patients with Buruli ulcer (RR, 0.36 [95% CI, .22-.58]) [23] . However, the study did not specify how many cases were laboratory confirmed; therefore, inclusion of osteomyelitis caused by pathogens other than NTM might have led to an overestimate of the rate of protection.
DISCUSSION
The protective effectiveness of BCG vaccination against Mycobacterium tuberculosis and Mycobacterium leprae is well recognized [24, 28] . There is also evidence that infection with NTM might confer protection against M. tuberculosis infection or interact with the effectiveness of BCG vaccination [29] [30] [31] . In contrast, whether BCG vaccination protects against NTM infections has been controversial.
Our review found strong evidence from large European surveillance studies that BCG vaccination protects against NTM lymphadenitis in children. The rate of NTM infections in Finland, when there was universal neonatal BCG vaccination, was 30 times lower than the rate in Sweden, which did not have universal neonatal BCG vaccination, despite both countries having similar environmental and epidemiological characteristics [18] . In addition, in the Czech Republic and in Sweden, a sharp increase in NTM infection in children was observed after stopping universal neonatal BCG vaccination [16, 17] .
For Buruli ulcer, there is strong evidence from two RCTs for a protective effect of BCG vaccination in the first year after the vaccination [19, 20] . The results of the case-control studies are difficult to interpret given their disparate findings. Furthermore, it is important to consider that the RCTs estimated the effectiveness of BCG vaccine under the optimal storage, handling, and administration conditions of a clinical trial [19, 20] , while this was not necessarily the case in the case-control studies [21, 22, 25, 27] . In addition to the study included in our review, which reports smaller skin lesions in patients with Buruli ulcer who have previously received a BCG vaccine [20] , another study (not included in this review because the BCG vaccination status was not reported in the control group) reported a shorter duration to healing [26] . A further study (not included due to incomplete data) suggested that BCG vaccination protects against severe forms of Buruli ulcer with multiple skin lesions [32] . In addition to the evidence from the study included in our review [23] , this study also indicates that BCG vaccination might protect patients with Buruli ulcer from progression to NTM osteomyelitis [32] . Notably, all but one of the studies reporting on the protective effect of BCG vaccination against Buruli ulcer assessed BCG vaccinations status only by the presence of a scar. Determining BCG vaccination status by the presence of a scar has a sensitivity of between 55% and 97% [33] [34] [35] and therefore its use may underestimate BCG vaccine effectiveness in comparative studies. However, the presence of a scar does not predict protection against tuberculosis [36, 37] , and failure to develop a BCG scar might be an indication of poor vaccination technique [38] . As this might also be the case for NTM disease, using the presence of a scar rather than administration of BCG could, on the contrary, also overestimate protection.
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There is some evidence to suggest that vaccine strain and genotype influence the protective effectiveness of BCG against M. tuberculosis [39] [40] [41] . It is therefore plausible that there is variation between different BCG strains in their protective effectiveness against NTM disease. The vaccine strains used in the studies included in this review varied considerably, precluding meaningful analysis.
A trial that included 121 020 people in Malawi showed that revaccination with BCG approximately halved the risk of leprosy compared with a single BCG vaccination, even though it did not protect against pulmonary tuberculosis [42] . It would be of interest to determine whether revaccination with BCG increases the strength or duration of protection against NTM.
A number of animal studies support the notion that BCG vaccination protects against NTM infection. Mice, rabbits, and guinea pigs vaccinated intracutaneously with BCG Dubos II are protected against M. avium administered intravenously [43] . Mice vaccinated with BCG Pasteur or Glaxo subcutaneously, intravenously or through the aerogenic route are protected against aerogenic infection with M. avium and Mycobacterium kansaii, but not against Mycobacterium simiae or Mycobacterium intracellulare [44, 45] . One study in mice found that the effectiveness of BCG vaccination against NTM infection varies according to differences in host conditions and different strains of M. ulcerans [46] .
Recent trials have investigated the possibility of developing vaccines with greater effectiveness against NTM. The mycobacterial antigen 85A has 85% amino acid sequence similarity in M. ulcerans and M. bovis. A DNA vaccine encoding this antigen protects mice against Buruli ulcer [47] . This vaccine has been further developed, combining antigen 85A from Mycobacterium smegmatis with BCG in a live-recombinant vaccine, and protects mice against Buruli ulcer [48] . A single immunization with a plasmid expressing the BCG antigen DNA-35 protects mice against infection with M. avium [49] .
The strengths of this review are the comprehensive literature search, the clearly defined inclusion criteria, and the use of meta-analysis to assess results from multiple studies. The main limitations are the heterogeneity between studies in design, including the use of different BCG strains. Further limitations are potential differences between the groups who received and did not receive BCG vaccine, such as epidemiological factors, access to healthcare, and intensity of surveillance. Additionally, the use of BCG scar to assess vaccination status in retrospective studies and the inclusion of non-laboratory-confirmed cases of NTM infection probably introduces bias. The risk of bias in the studies is summarized in Table 5 .
Overall, our review and meta-analysis indicates that BCG vaccination protects against NTM. It is likely that effectiveness of BCG vaccination varies between different NTM diseases, populations, age groups, and the BCG strain used to vaccinate. The increase in incidence of NTM lymphadenitis in industrialized countries that have discontinued universal BCG vaccination might therefore be related to the loss of protection afforded by this vaccine.
Our review suggests that the protective effect of BCG vaccination against NTM should be taken into consideration when deciding on recommendations for discontinuation of universal BCG vaccination programs and in assessing new vaccines designed to replace BCG. In deciding vaccine policy, the incidence and the severity of the disease, as well as the NNT, are important considerations. The NNT with BCG vaccine to prevent one case of NTM lymphadenitis is probably unjustifiably high when considered in isolation, as NTM lymphadenitis is relatively rare and usually has a favorable outcome despite a frequently long and troublesome course. In contrast, Buruli ulcer is a serious condition with crippling sequelae and has been identified by the WHO as an emerging public health problem. The potential importance of BCG vaccination for preventing Buruli ulcer has been recognized in a recent WHO position paper [50] .
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